Combining AI Models Improves Breast Cancer Risk Assessment

Combining AI systems for short- and long-term breast cancer risk results in an improved cancer risk assessment, according to a study published in Radiology.

Using mammography-based deep learning models may improve the accuracy of breast cancer risk assessment and can also lead to earlier diagnoses.

“About 1 in 10 women develop breast cancer throughout their lifetime,” said study author Andreas D. Lauritzen, PhD, from the Department of Computer Science at the University of Copenhagen in Denmark. “In recent years, AI has been studied for the purpose of diagnosing breast cancer earlier by automatically detecting breast cancers in mammograms and measuring the risk of future breast cancer.”

Diagnostic AI models are trained to detect suspicious lesions on mammograms and are well suited to estimate short-term breast cancer risk.

More suitable for long-term breast cancer risk are texture AI models, capable of identifying breast density. Women with dense breast tissue are at higher risk of developing breast cancer and may benefit from supplemental MRI screening.

“It is important to enable reliable and robust assessment of breast cancer risk using information from the screening mammogram,” Dr. Lauritzen said.

Lauritzen Ry Fig 4
Full-Field Digital Mammograms (Right Mediolateral Oblique View) In A 59-Year-Old Woman Show (A) The Screening Mammogram Obtained During The Study Period And (B) The Screening Mammogram Obtained In The Subsequent Screening Round. The First Screening Mammogram (A) Had A Very Low Combined Risk Score (Lowest 0.1%) As Determined By The Combination Model With Texture Risk And The Examination Score. The Woman Was Not Recalled And Did Not Receive A Breast Cancer Diagnosis Throughout The 5-Year Follow-Up.

Risk Assessment Better for Interval and Long-Term Cancer Detection

For this study, Dr. Lauritzen and his research team sought to identify whether a commercially available diagnostic AI tool and an AI texture model, trained separately and then subsequently combined, may improve breast cancer risk assessment.

The researchers used the diagnostic AI tool Transpara and a texture model that was developed by the researchers. A Dutch training set of over 39,000 exams was used to train the models. The short- and long-term risk models were combined using a three-layer neural network.

The combined AI model was tested on a study group of more than 119,000 women who were included in a breast cancer screening program in the Capital Region of Denmark between November 2012 and December 2015. The average age of the women was 59 years.

Compared to the diagnostic and texture models alone, the combined AI model showed an overall improved risk assessment for both interval and long-term cancer detection.

The model also enabled identification of women at high risk for breast cancer. Women identified by the combined model as having the 10% highest combined risk accounted for 44.1% of interval cancers and 33.7% of long-term cancers.

Listen as Dr. Lauritzen, PhD, discusses his research.

Using AI to identify a women’s breast cancer risk from a single mammogram will not only result in earlier cancer detection but can also improve the strain on the health care system due to the worldwide shortage of specialized breast radiologists.

“Current state-of-the-art clinical risk models require multiple tests such as blood work, genetic testing, mammogram and filling out extensive questionnaires, all of which would substantially increase the workload in the screening clinic,” Dr. Lauritzen said. “Using our model, risk can be assessed with the same performance as the clinical risk models but within seconds from screening and without introducing overhead in the clinic.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy